Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Airbnb, Inc. (ABNB) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

Airbnb, Inc.Trade
Amylx Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Airbnb, Inc. vs Amylx Pharmaceuticals Inc — how do they compare? Airbnb, Inc. trades at $180.53 (market cap $110.76B), while Amylx Pharmaceuticals Inc trades at $23.7 (market cap $2.64B). The key difference: Airbnb, Inc. is far larger — about 42× Amylx Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

ABNBAMLX
Market Cap
$110.76B$2.64B
Sector
Consumer CyclicalHealth
52-Week High
$184.98$24.19
52-Week Low
$111.54$7.82
Enterprise Value
$101.19B$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Airbnb, Inc.

ABNB trades at $180.06, down 2.51% today but remains near recent highs following strong Q2 2026 earnings that beat expectations. The stock shows bullish technical momentum with moving averages supporting upward trends, though oscillators indicate potential overbought conditions. Fundamentally, Airbnb demonstrates robust revenue growth with $12.24B in 2025 revenue and impressive 82.9% gross margins, though valuation multiples remain elevated with a P/E of 42.23. Recent news highlights the company's strategic pivot toward AI integration and expansion into hotel listings and travel services.

The outlook remains positive with analyst consensus leaning toward Buy (46.7% of ratings) and a $173.26 price target, though current price exceeds this consensus. Key opportunities include AI-driven efficiency gains and travel demand recovery, while risks involve premium valuation sensitivity and competitive pressures in the evolving travel marketplace. Institutional sentiment appears cautiously optimistic given recent earnings momentum.

Amylx Pharmaceuticals Inc

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Airbnb, Inc.

Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.

Read more on ABNB

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX